GENELUX Corp
GNLXGenelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable DNA virus with a large engineering capacity.
Drugs in Pipeline
4
Phase 3 Programs
1
Upcoming Catalysts
2
Next Catalyst
Aug 6, 2026
TomorrowMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
GNLX Earnings Report
EPS Est: $-0.20 | FQ end 2026-06
1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How GNLX's past catalysts played out
olvimulogene nanivacirepvec
Platinum-resistant Ovarian Cancer
GL-ONC1
Peritoneal Carcinomatosis
Platinum chemotherapy: carboplatin or cisplatin
Advanced Non-squamous Non-small-cell Lung Cancer
Olvi-Vec
Ovarian Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
olvimulogene nanivacirepvec | Phase 3 | Platinum-resistant Ovarian Cancer | - | - |
GL-ONC1 | Phase 2 | Peritoneal Carcinomatosis | - | - |
Platinum chemotherapy: carboplatin or cisplatin | Phase 2 | Advanced Non-squamous Non-small-cell Lung Cancer | - | - |
Olvi-Vec | Phase 2 | Ovarian Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in GENELUX Corp's drug pipeline?→
CatalystAlert tracks 4 drug candidates in GENELUX Corp's (GNLX) pipeline across Phase 3, Phase 2. Its lead program is olvimulogene nanivacirepvec (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is GENELUX Corp's next FDA catalyst?→
GENELUX Corp's (GNLX) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track GNLX biotech catalysts?→
Add GNLX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow GENELUX Corp's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.